We recently spoke about virtual and hybrid clinical trials with Amy O’Sullivan, Director of North American Operations at SCOPE International, an independent full-service CRO serving pharma, biotech, and medical device clients across the US and Europe. The company is headquartered in Mannheim, Germany, with US operations based in Pittsburgh, PA.
Today, ArcheMedX, a leader in behavior-based learning and operational insights for life sciences and healthcare organizations, announced the results of its new survey, “COVID-19's Impact on Virtual Tech in Clinical Trials.” The findings reveal brand-new insights into how clinical trial leaders in pharmaceuticals, biotech, and clinical research organizations are accelerating
Choosing the right way to train clinical trial staff is complex and exhausting under normal circumstances. Today’s immense pressure to accommodate new virtual working styles across investigator meetings, site selection, and site initiation visits magnifies those challenges.
As we revealed in our recent report, clinical operations leaders are adopting virtual tools
Making it through the clinical trial start-up process is critical for any study - and takes a lot of effort under normal circumstances. But today, with the need to conduct more and more clinical operations remotely - it’s even more challenging.
The good news is that there is a way forward,
Until the recent changes forced upon our industry by COVID-19, clinical research has been anything but digital: instead, relying heavily on in-person interaction, monitoring, and data collection.
Many trials have been forced to halt, or change standard operating procedures (SOPs) in order to restart. The adoption of digital solutions has accelerated.
We recently spoke with Kemi Olugemo, M.D., Executive Medical Director, Neurology Clinical Development at Akcea Therapeutics. Akcea is a development and commercialization company focused on helping patients with serious diseases. The company is based in Boston, MA. Here are some of the most interesting excerpts from our discussion:
You’re a neurologist